- Report
- October 2024
- 190 Pages
Global
From €3181EUR$3,545USD£2,738GBP
€3534EUR$3,939USD£3,042GBP
- Report
- March 2025
- 175 Pages
Global
From €4029EUR$4,490USD£3,467GBP
- Report
- July 2024
- 142 Pages
Global
From €2691EUR$2,999USD£2,316GBP
- Report
- July 2024
- 162 Pages
Africa
From €2243EUR$2,500USD£1,931GBP
- Report
- October 2023
- 75 Pages
Global
From €5339EUR$5,950USD£4,595GBP
- Report
- March 2024
- 118 Pages
Global
From €4038EUR$4,500USD£3,475GBP
- Clinical Trials
- January 2024
- 60 Pages
Global
From €1122EUR$1,250USD£965GBP
- Report
- May 2023
- 160 Pages
Global
From €4441EUR$4,949USD£3,822GBP
- Report
- January 2025
- 95 Pages
Global
From €3500EUR$4,178USD£3,118GBP
The Fusion Inhibitor market is a subset of the HIV/AIDS Drugs market. Fusion Inhibitors are a type of antiretroviral drug used to treat HIV/AIDS. They work by blocking the fusion of the HIV virus with the host cell, thus preventing the virus from entering the cell and replicating. Fusion Inhibitors are usually used in combination with other antiretroviral drugs to maximize their effectiveness.
Fusion Inhibitors are generally well tolerated and have few side effects. They are also relatively easy to administer, as they are usually taken orally. However, they are not as effective as other antiretroviral drugs, and may not be suitable for all patients.
Some of the companies in the Fusion Inhibitor market include Gilead Sciences, Merck, ViiV Healthcare, and Bristol-Myers Squibb. Show Less Read more
